Table 2.
Clinical characteristics and outcome of 14 eligible patients with recurrent ependymoma treated with BVZ + CPT-11
| Patient No. | Age/Sex | Tumor Grade | No. of Prior Recurrences/Site of Recurrence/Size (cm) | Prior Therapy (interval post-XRT, y)/interval from last therapy to enrollment (mo) | No. of Courses | Outcome |
|---|---|---|---|---|---|---|
| 1 | 4.2/F | III | 1/lateral ventricle (1.2 × 0.8) | Surgery/focal XRT (2.4)/29 | 2 | Local PD |
| 2 | 5.3/M | II | 3/Infrantentorial (NOS) (2.3 × 3.2) | Surgery, CTX, CDDP, VCR, VP-16, CSI + focal XRT, oral VP-16 (1.1)/1 | 2 | Local PD |
| 3 | 9.7/M | II | 1/IV ventricle (3.7 × 1.5) | Surgery/focal XRT (1.6)/19 | 2 | Local PD |
| 4 | 9.5/M | II | 3/Infratentorial (NOS) | Surgery, CTX, VCR, focal XRT (8.1)/1 | 3 | Local PD |
| 5 | 9.4/M | II | 2/Spinal cord (2.8 × 2.2) | Surgery, Focal XRT (6.9)/83 | 4 | Local PD |
| 6 | 4.8/F | II | 1/Cerebellum (2.1 × 1.4) | Surgery, focal XRT (2.3)/27 | 2 | Local PD |
| 7 | 12.4/M | II | 4/Infratentorial (NOS) (1.4 × 1.0) | Surgery, focal XRT x4 (6.0)/72 | 2 | Local PD |
| 8 | 8.9/M | III | 3/IV ventricle (0.5 × 0.5) | Surgery, focal XRT, CTX, VCR, CDDP, VP-16; oral VP-16, 13- CR, celocoxib, TMZ (1.6)/6 | 2 | Local PD |
| 9 | 7.1/F | III | 1/IV ventricle (0.9 × 0.9) | Surgery, focal XRT (1.4)/17 | 4 | Local PD |
| 10 | 16.7/M | II | 2/Cerebellum (2.2 × 2.0) | Surgery, focal XRT (1.5)/18 | 12 | SD/off Rx for toxicity |
| 11 | 14.7/F* | III | 5/Parietal Lobe (1.3 × .1.2) | Surgery, focal XRT, enzastaurin, pannitumab (NA)/0.6 | 2 | PD/spinal cord |
| 12 | 7.7/F | II | 5/Cerebellum (3.2 × 3) | Surgery, HDC, VCR, carboplatin, VP-16, TMZ, celocoxib, focal XRT (3.2)/0.3 | 7 | Local PD |
| 13 | 13/M | II | 3/Infratentorial (NOS) (2.9 × 2.2) | Surgery, VCR, carboplatin, CTX, focal XRT, AZD2171 (3.1)/0.8 | 10 | SD/off Rx for toxicity |
| 14 | 3/F | II | 0/Frontal lobe (1.9 × 0.8) | Surgery, focal XRT (0.8)/10 | 4 | SD/off Rx for refusal to follow-up |
Abbreviations: XRT, radiotherapy; CR, cis–retinoic acid CTX, chemotherapy; CDDP, cisplatin; VCR, vincristine; VP-16, etoposide; CSI, craniospinal irradiation; TMZ, temozolomide; HDC, high-dose chemotherapy; NOS, not otherwise specified. * The patient was not evaluable owing to receiving incorrect doses of the study drug.